Compare Hilton Hotels Corporation Common Stock (HLT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Hilton Hotels Corporation Common Stock trades at $323.97 (market cap $70.82B), while State Street SPDR S&P Biotech ETF trades at $159. The key difference: Hilton Hotels Corporation Common Stock pays a 0.19% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hilton Hotels Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| HLT | XBI | |
|---|---|---|
Market Cap | $70.82B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $350.22 | $164.28 |
52-Week Low | $256.75 | $86.92 |
Enterprise Value | $83.83B | — |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide Holdings (HLT) trades at $322.51, up 3.7% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains solid fundamentals with revenue growth to $12.04B in 2025 and net income of $1.46B. Recent news highlights labor strikes and executive stock sales, while analyst consensus remains bullish with a $352 price target.
HLT offers growth potential from travel recovery and pipeline expansion, but faces risks from premium valuation (P/E 46.21), rising debt levels, and operational challenges. The stock trades near resistance at $316-$319, requiring strong Q3 earnings to sustain momentum amid mixed technical indicators.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
